Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies.
Share this article
Corporate
Score 65
Bearish
Amgen Inc. (AMGN) Collaborates on Ending Anti-OX40 Clinical Studies
Mar 15, 2026 18:45 UTC
AMGN, XLV, IYH
Short term
Related Articles
Score 35
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
Mar 15, 19:59
Score 35
Bearish
Another popular barbecue chain files for Chapter 11 bankruptcy
Mar 15, 19:53
Score 75
Bearish
Meta weighs drastic workforce decision after $135 billion guide
Mar 15, 19:50
Score 85
Bullish
Elon Musk Unmasks Joint Project Between Tesla (TSLA) and xAI, Reuters Reports
Mar 15, 19:36
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.